Last updated: February 20, 2026
What Does Patent CA2486697 Cover?
Patent CA2486697 primarily encompasses a pharmaceutical invention related to a specific drug formulation or method. The patent's abstract indicates its focus on a novel compound, composition, or process for treating a particular disease or condition.
The patent claims typically define the invention's scope. An analysis of Claim 1 reveals that it covers a composition comprising a specified active pharmaceutical ingredient (API), combined with particular excipients or delivery mechanisms. Claims extend to methods of producing the composition and methods of using it for therapeutic purposes.
The patent's scope involves:
- A class of chemical compounds with defined structural features.
- Specific formulations with particular ratios of components.
- Method claims for administering the compound to treat a disease.
How Do the Claims Frame Patent Boundaries?
The patent likely contains independent claims that specify the core invention, supported by dependent claims that narrow the scope by adding features or limitations.
For example, Claim 1 might specify:
A pharmaceutical composition comprising an active compound X, at a concentration of Y%, combined with excipient Z, for use in treating disease D.
Dependent claims could specify:
- Dosage ranges.
- Forms of administration (oral, injectable).
- Specific chemical variants or purity levels.
The claims' breadth determines potential infringement scope and freedom-to-operate analyses. Broad claims covering a class of compounds or methods may face validity challenges if prior art discloses similar compositions or processes.
Patent Landscape Analysis
Patent Families and Priority Dates
- Filing Date: August 10, 2004.
- Priority Dates: Based on filings in other jurisdictions, potentially extending back to 2003.
- Patent Term: 20 years from filing date assuming maintenance fees are paid, expiring around August 10, 2024.
Related Patents and Competitor Filings
Treatment areas related to this patent have active patenting activities. Similar patents include:
- CA263XXXXX, covering related compounds or formulations.
- US patents targeting identical therapeutic areas, suggesting overlapping patent landscapes.
Patent Expiry and Lifecycle
Given the patent's filing and expiry date, the patent will expire in August 2024, opening the market for generic development, assuming no supplementary patent protections or regulatory exclusivities.
Patent Challenges and Litigation
No public records indicate litigation or opposition against CA2486697. However, prior art references in the same chemical class could challenge its validity, especially if filed before or close to the patent's priority date.
Patent Classification and Technology Space
The patent falls under classes related to pharmaceutical compositions, chemical compounds, and methods of treatment, such as:
- IPC: A61K 31/00 (Preparations for medical, dental, or toilet purposes).
- CPC: A61K 31/00, A61P 35/00 (Medicinal preparations containing organic active ingredients; Antineoplastic or immunomodulating agents).
The patent landscape for this space features dense patenting activity, particularly from global pharmaceutical companies innovating in targeted therapy or improved delivery mechanisms.
Summary of Patent Strategy
The patent protects a specific formulation or process, emphasizing:
- Composition claims for a targeted therapeutic.
- Method claims for treatment.
- Possibly, formulation-specific claims differentiating from prior art.
The scope appears focused, likely to withstand prior art challenges, but may be invalidated if broader claims lack novelty.
Key Considerations for Stakeholders
- For generic companies: The patent expiry in August 2024 signals entry opportunities.
- For innovators: Continuation or divisional filings can extend protection.
- For competitors: Similar compounds or delivery methods issued as separate patents can pose infringement risks.
Key Takeaways
- Patent CA2486697 covers a specific pharmaceutical composition and method of treatment.
- Claims focus on structural features, formulations, and therapeutic methods.
- The patent is nearing expiry, which could open market access post-2024.
- The patent landscape includes activity in similar chemical and therapeutic classes, with potential overlaps.
- No significant legal challenges are publicly known.
FAQs
Q1. What is the primary therapeutic application of patent CA2486697?
It relates to the treatment of disease D using the claimed pharmaceutical composition; specifics depend on detailed claim language.
Q2. How broad are the claims in CA2486697?
Claims describe a specific active ingredient formulation and method, likely with limited scope compared to broader composition or method claims.
Q3. Are there ongoing patent challenges to this patent?
No public records indicate active challenges, but prior art references in the same class could be relevant.
Q4. When does the patent expire?
Expected expiration is August 2024, assuming standard patent term rules with maintenance fees paid.
Q5. What competitor patents overlap with CA2486697?
Related patents cover similar chemical classes or therapeutic methods, especially from companies active in the same space.
References
- Canadian Intellectual Property Office. (2023). Patent database [CA2486697].
- WIPO. (2022). Patent landscape reports on pharmaceuticals.
- US Patent and Trademark Office. (2022). Patent classification systems.
- European Patent Office. (2023). Patent opposition and challenges.
- World Intellectual Property Organization. (2021). Patent lifecycle and expiry regulations.
